<DOC>
	<DOCNO>NCT02123732</DOCNO>
	<brief_summary>This 2-arm , single-blind , crossover , placebo-controlled clinical study , 24 week therapy evaluate efficacy safety DbXell improve metabolic control patient Type 2 Diabetes mildly uncontrolled , define HbA1c target le 8.0 % current conventional therapy .</brief_summary>
	<brief_title>Role DbXell Treatment Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female subject age 1870 year Established type 2 diabetes mellitus define American Diabetes Association , duration le 10 year . Suboptimal glycemic control judge HbA1c target 8.0 % .Current medication 2 oral hypoglycemic agent . No current past insulin GLP1 therapy . FPG ≤ 180 mg/dL Hemoglobin level ≥ 10.0 g/dL Serum ALT ≤ 2.5 time upper limit normal Serum creatinine &lt; 1.5 time upper limit normal Female childbearing potential Subjects symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , symptomatic ischemic arterial disease necessitate medical treatment Uncontrolled hypertension ( SBP &gt; 160 mmHg and/or DBP &gt; 100 mmHg ) History renal and/or liver disease History presence clinical evidence malignancy Presence exacerbation chronic illness , severe acute infection , complicate infection Current treatment systemic corticosteroid herbal ( alternative ) medicine Participation intervention trial within 30 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Herbal</keyword>
	<keyword>food supplement</keyword>
</DOC>